Boston Scientific launches Alair asthma treatment in India

Boston Scientific (NYSE:BSX) has launched its Alair bronchial thermoplasty therapy in India, according to an India Blooms report. The device won clearance in the country with indications for treating severe, persistent, drug-resistant asthma in adult patients who’s asthma is not well controlled with inhaled corticosteroids and long acting beta antagonists. Marlborough, Mass.-based Boston Scientific’s Alair bronchial thermoplasty treatment uses a bronchoscope to deliver radiofrequency energy to reduce the amount of excess smooth muscle tissue in the airways. “There are over 18 million estimated asthmatics in the country, for some of whom currently available medication has failed to provide any relief. Our bronchial thermoplasty therapy holds great promise to help address this need gap. We have sufficient evidence that shows Bronchial Thermoplasty is an effective therapeutic option for patients with severe persistent, drug-resistant asthma,” Boston Scientific India VP & managing director Prabal Chakraborty said, according to the report. The 1st procedure using the device was performed at the Royal Care Hospital in Coimbatore yesterday, according to India Blooms. “This is a ground-breaking solution which may provide a complementary treatment to severe, persistent, drug-resistant asthma patients in the country,” operating physician in the 1st procedure Dr. Pattabi Raman of the Royal Care Super Specialty Hospital said, according to the rep...
Source: Mass Device - Category: Medical Devices Authors: Tags: Regulatory/Compliance Respiratory Boston Scientific Source Type: news